ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1459

Enhanced Efficacy of Early Vs. Late IL-1β Antagonism in Murine Arthritis Mediated By Deficiency of the IL-1 Receptor Antagonist IL-1ra

Anais Levescot1, Allyn Morris2 and Peter Nigrovic3, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, boston, MA, 2Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: IL-1, Systemic JIA and mouse model

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Animal Models - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  IL-1 blockade is highly effective for systemic juvenile idiopathic arthritis (sJIA), but clinical observations raise the possibility that initiation of treatment in a “window of opportunity” before chronic arthritis develops may be more effective than in latyers disease. We have hypothesized that sJIA is a biphasic process in which an initial IL-1β-driven systemic phase gives rise to IL-17-driven chronic inflammatory arthritis. We sought to test this hypothesis in the IL-1ra-/-model, a spontaneous T cell-mediated murine arthritis dependent upon both IL-1β and IL-17.

Methods:  IL-1ra-/-mice were treated with anti-mIL-1β or isotype-matched IgG (5mg/kg i.p. 2 times per week) for 2 weeks, beginning either 3 days after arthritis onset (early treatment) or 3 weeks after arthritis treatment (late treatment). Arthritis score (0-3/per paw, 0-12 total) and ankle and wrist thickening measured by caliper were followed for 54 days after arthritis onset. Synovial tissue was harvested at day 54 for flow cytometry to characterize lymphocyte surface phenotype and cytokine production.

Results:  Clinical indices were reduced in both treatment groups compared with isotype control, without a difference between groups. However, joint thickening was reduced in early compared with late treatment, although worsening was again noted after anti-IL-1β was discontinued. Histological injury was minimized in the early treatment group, suggesting that early IL-1β antagonism was more efficient. In support of this possibility, early anti-IL-1β abrogated accumulation of lymphocytes expressing IFN-γ and IL-17A, while treatment of established disease resulted only in modest reduction of IL-17A-expressing cells. Consistent with published findings, γδT cells represented on average slightly more than half of all synovial CD3+cells. The reduction in IL-17-expressing lymphocytes paralleled the lower abundance of this population after either early or late treatment, with an intriguing trend toward greater reduction in γδT cells in the early treatment group, corresponding to the reduction in synovial lymphocytes expressing IL-17.

Conclusion:  In murine IL-1ra-/- synovitis, early IL-1β blockade more efficiently reduces tissue injury and lymphocyte accumulation than late blockade, although both are effective. Efficacy correlated with a reduction in IL-17-producting cells, and in particular with fewer IL-17-producing gdT cells. These findings support the hypothesis that early IL-1β blockade could represent an effective strategy to modulate the development of arthritogenic T cells in IL-1-driven arthritis, a result that may inform the understanding and treatment of sJIA.


Disclosure: A. Levescot, None; A. Morris, None; P. Nigrovic, Novartis Pharmaceutical Corporation, 2,Novartis Pharmaceutical Corporation, 5,Sobi, Inc., 2,Sobi, Inc., 5,Alkermes, 5.

To cite this abstract in AMA style:

Levescot A, Morris A, Nigrovic P. Enhanced Efficacy of Early Vs. Late IL-1β Antagonism in Murine Arthritis Mediated By Deficiency of the IL-1 Receptor Antagonist IL-1ra [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/enhanced-efficacy-of-early-vs-late-il-1%ce%b2-antagonism-in-murine-arthritis-mediated-by-deficiency-of-the-il-1-receptor-antagonist-il-1ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhanced-efficacy-of-early-vs-late-il-1%ce%b2-antagonism-in-murine-arthritis-mediated-by-deficiency-of-the-il-1-receptor-antagonist-il-1ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology